It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBOT’s FA Score shows that 1 FA rating(s) are green whileEPRX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBOT’s TA Score shows that 5 TA indicator(s) are bullish while EPRX’s TA Score has 5 bullish TA indicator(s).
BBOT (@Biotechnology) experienced а -8.28% price change this week, while EPRX (@Biotechnology) price change was +10.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.
BBOT is expected to report earnings on Sep 02, 2026.
EPRX is expected to report earnings on Aug 07, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BBOT | EPRX | BBOT / EPRX | |
| Capitalization | 648M | 419M | 155% |
| EBITDA | -168.12M | -47.14M | 357% |
| Gain YTD | -35.383 | -15.232 | 232% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 0 | - |
| Total Cash | 252M | 139M | 181% |
| Total Debt | 2.64M | 2.01M | 132% |
| BBOT | EPRX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 33% | N/A |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 27% | 3 days ago 70% |
| MACD ODDS (%) | 3 days ago 36% | 3 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 44% | 3 days ago 48% |
| TrendMonth ODDS (%) | 3 days ago 44% | 3 days ago 60% |
| Advances ODDS (%) | 12 days ago 63% | 12 days ago 79% |
| Declines ODDS (%) | 5 days ago 69% | 5 days ago 74% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 80% |
| Aroon ODDS (%) | 3 days ago 48% | 3 days ago 63% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| USLCX | 29.30 | 0.37 | +1.28% |
| JHancock U.S. Global Leaders Growth C | |||
| JLPZX | 20.18 | 0.20 | +1.00% |
| JPMorgan US Large Cap Core Plus R2 | |||
| ADSIX | 23.06 | 0.13 | +0.57% |
| American Century Disciplined Growth Inv | |||
| DFEOX | 55.40 | 0.26 | +0.47% |
| DFA US Core Equity 1 I | |||
| TSLCX | 5.80 | N/A | N/A |
| Transamerica Small Cap Value C | |||
A.I.dvisor indicates that over the last year, BBOT has been loosely correlated with VKTX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if BBOT jumps, then VKTX could also see price increases.
| Ticker / NAME | Correlation To BBOT | 1D Price Change % | ||
|---|---|---|---|---|
| BBOT | 100% | -4.82% | ||
| VKTX - BBOT | 33% Loosely correlated | -4.14% | ||
| EPRX - BBOT | 27% Poorly correlated | -2.29% | ||
| LCTX - BBOT | 27% Poorly correlated | -2.70% | ||
| MSLE - BBOT | 26% Poorly correlated | +3.42% | ||
| NKTX - BBOT | 26% Poorly correlated | -2.79% | ||
More | ||||
A.I.dvisor tells us that EPRX and LCTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPRX and LCTX's prices will move in lockstep.
| Ticker / NAME | Correlation To EPRX | 1D Price Change % | ||
|---|---|---|---|---|
| EPRX | 100% | -2.29% | ||
| LCTX - EPRX | 32% Poorly correlated | -2.70% | ||
| NAGE - EPRX | 32% Poorly correlated | +2.41% | ||
| NTLA - EPRX | 31% Poorly correlated | -3.70% | ||
| ABCL - EPRX | 30% Poorly correlated | +0.35% | ||
| COGT - EPRX | 30% Poorly correlated | -5.88% | ||
More | ||||